Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | NAPEPLD | Q6IQ20 | 17/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23684473 | 0.91 | EHMT2 (0.34) | EHMT2EHMT1NAPEPLDPRMT5WDR77 | |
| SCHEMBL23304427 | 0.90 | NAPEPLD (0.39) | EHMT2EHMT1NAPEPLDPRMT5WDR77 | |
| SCHEMBL25062941 | 0.90 | NAPEPLD (0.39) | NAPEPLD | |
| SCHEMBL23304367 | 0.89 | NAPEPLD (0.39) | EHMT2EHMT1NAPEPLDPRMT5WDR77 | |
| SCHEMBL30260151 | 0.88 | NAPEPLD (0.41) | EHMT2EHMT1NAPEPLDPRMT5WDR77 | |
| SCHEMBL25063004 | 0.83 | NAPEPLD (0.40) | EHMT2EHMT1NAPEPLD | |
| SCHEMBL23304386 | 0.81 | PIK3CA (0.40) | EHMT2EHMT1NAPEPLD | |
| SCHEMBL23329909 | 0.81 | NAPEPLD (0.40) | EHMT2EHMT1NAPEPLD | |
| SCHEMBL17303810 | 0.80 | HCRTR1 (0.37) | EHMT2EHMT1 | |
| SCHEMBL23684701 | 0.79 | NAPEPLD (0.36) | EHMT2EHMT1NAPEPLDPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | EHMT2 4405/4885EHMT1 4107/4885NAPEPLD 2065/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | EHMT2 4173/4885EHMT1 3952/4885NAPEPLD 1362/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | EHMT2 4405/4885EHMT1 4107/4885NAPEPLD 2065/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | EHMT2 4173/4885EHMT1 3952/4885NAPEPLD 1362/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | EHMT2 4405/4885EHMT1 4107/4885NAPEPLD 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.